And new data on one drug, Zyprexa (olanzapine), will likely be submitted to the FDA this year in anticipation of earning a pediatric indication for either schizophrenia or bipolar disorder, Dr. Correll said.
At the least, new pediatric data on Zyprexa should appear in peer-reviewed journals in 2007, Dr. Correll said.
Dr. Correll is a lecturer or consultant for Eli Lilly, AstraZeneca, Bristol-Myers Squibb, Janssen, Solvay Pharmaceuticals, Otsuka Pharmaceutical Group, and Intra-Cellular Therapies.
New guidance on the monitoring and management of diabetes and metabolic syndrome in children and adults on antipsychotic drugs could also be forthcoming in 2007, Dr. Correll said.
